At week @ , and with > @ years of golimumab , overall intent-to-treat Assessment in SpondyloArthritis international Society criteria for @ % improvement ( ASAS@ ) and ASAS@ response rates were @ % ( @/@ ) and @ % ( @/@ ) , respectively ; Bath AS Disease Activity Index @ % improvement response was @ % ( @/@ ) .